All News

At the annual MPN Heroes event, Dr. David Fajgenbaum, who discovered a treatment for his own rare disorder, shared insights on turning hope into action when faced with adversity.

Here is a list of clinical trials that are currently happening within the kidney cancer space.

Choosing a gift for the person with cancer can be challenging. In this post, survivor Bonnie Annis offers some helpful information by sharing thoughts as she remembers her own past Christmases.

From better breast cancer screening options for service members and their families to a Christmas display that’s raising cancer awareness, here’s what is making headlines in the cancer space this week.

Two-time cancer survivor Anne Weber feels fortunate to have learned of her BRCA2 gene mutation, as it led to an early diagnosis of aggressive breast cancer.

New research suggests men with infertility could face a 30% to 60% higher risk of prostate cancer.

A new study suggests the common pill could help prevent deaths from cancer, but it’s not without it's share of side effects.

Rebuilding your life after a kick in the gut is all about your mindset.

In cancer clinical trials, the goal, or primary endpoint, is often focused on overall survival. However, one expert from the Dana Farber Cancer Institute thinks treatment-free survival should also be documented to provide patients with the data they need to make informed treatment choices.

What do erasers, drawings, cancer and life all have in common? More than you might think.

The Food and Drug Administration approved Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations.

Marijuana use is gaining cultural acceptance as a way to ease discomfort in patients with cancer, but is it safety is still unclear.

How do you heal your mind when faced with cognitive impairment after cancer treatment?

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.

The FDA accepted a supplemental biologics license application (sBLA) and granted a priority review to Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to AstraZeneca, the drug’s manufacturer.

Living life means living with the risk of cancer. It is interesting to contemplate how the cards are dealt even as we try to outwit fate.

The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.

There is plenty of scientific data about the physical challenges patients with cancer endure, but more is needed to address psychosocial issues.

Here are the top five CURE® stories for November 2019.

Patient advocate and lung cancer survivor Nancy Cohen discusses living with stage 4 lung cancer.

"When diagnosed with breast cancer, it helped for me to reflect daily upon my gratitude list as a way to overcome adversity."

Here is a list of the recent trial initiations that occurred within the cancer space in November.

It's not always as simple as just going "all in" on healing.

From the first patient death under the Right to Try law to a 9-year-old ovarian cancer survivor meeting her hero Jim Cantore, here’s what is making headlines in the cancer space this week.

One survivor accepts her nontraditional meal this year and embraces cancer’s lessons.

In this week’s “CURE Talks Cancer” podcast, we spoke with Michelle Velez, who developed a rare gynecological cancer following a molar pregnancy.

The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.

Keeping traditions “normal” while facing cancer can wear patients down.

Although one in nine men will receive a prostate cancer diagnosis in his lifetime, cutting-edge research has allowed more men to live longer or even be cured.

Here’s a look at what’s inside our November 2019 Lung Cancer special issue.